Bridgeway Capital Management’s Asterias Biotherapeutics Warrants AST.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
– Sell
-29,609
Closed -$15K – 1509
2017
Q2
$15K Hold
29,609
– – ﹤0.01% 1407
2017
Q1
$13K Hold
29,609
– – ﹤0.01% 1381
2016
Q4
$16K Hold
29,609
– – ﹤0.01% 1396
2016
Q3
$15K Sell
29,609
-1
-0% – ﹤0.01% 1417
2016
Q2
$6K Buy
+29,610
New +$15.4K ﹤0.01% 1427

Bridgeway Capital Management's AST.WS Position: Q3 2017 in Review

Bridgeway Capital Management sold out of Asterias Biotherapeutics Warrants (AST.WS) in Q3 2017, closing a stake of 29,609 shares — an estimated $15K sold.

Bridgeway Capital Management first reported a position in AST.WS in Q2 2016 and held it in 5 quarters. The position peaked at $16K in Q4 2016. 3 funds tracked by Wall St. Rank hold AST.WS as of Q3 2017.

  • Bridgeway Capital Management reported no remaining Asterias Biotherapeutics Warrants position as of Q3 2017 after selling out during the quarter.
  • Bridgeway Capital Management sold 29,609 Asterias Biotherapeutics Warrants shares in Q3 2017, an estimated $15K.
  • Bridgeway Capital Management first reported a position in Asterias Biotherapeutics Warrants in Q2 2016 and held it in 5 quarters.
  • Bridgeway Capital Management's Asterias Biotherapeutics Warrants position peaked at $16K in Q4 2016.
  • 3 funds tracked by Wall St. Rank held Asterias Biotherapeutics Warrants as of Q3 2017.

Based on Bridgeway Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.